Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from GlaxoSmithKline ( (GSK) ).
On 13 March 2026, GSK reported that its US president, Maya Martinez-Davis, acquired a small number of notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction, executed on the New York Stock Exchange at a price of $53.39 per ADS for 129.152 notional ADS, represents routine dealing by a senior executive and underscores ongoing alignment of management incentives with shareholder interests.
The notification, filed with the U.S. Securities and Exchange Commission on 17 March 2026, forms part of GSK’s regular disclosure obligations for transactions by persons discharging managerial responsibilities. While modest in scale, such reported dealings provide investors with additional transparency around executive exposure to GSK’s equity-linked instruments and the company’s approach to long-term compensation structures.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company that focuses on uniting science, technology and talent to develop medicines and vaccines aimed at getting ahead of disease. Headquartered in London and listed in both the U.K. and U.S. via ordinary shares and American Depositary Shares, it operates across major pharmaceutical and vaccine markets worldwide.
Average Trading Volume: 5,256,325
Technical Sentiment Signal: Buy
Current Market Cap: $107.9B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.